Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Ginsenoside Rg3 improves transarterial chemoembolization treatment in Chinese patients with advanced hepatocellular carcinoma

Date

20 Dec 2015

Session

Gastrointestinal tumours

Presenters

BO Zhou

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

B. Zhou

Author affiliations

  • Interventional Radiology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
More

Aim/Background

This single-center, open-label, randomized, controlled trial aimed to evaluate the efficacy and safety of ginsenoside Rg3, a low toxicity vascular-endothelial growth factor (VEGF) inhibitor, when used to supplement transarterial chemoembolization (TACE).

Methods

Advanced hepatocellular carcinoma (HCC) patients with no prior systemic therapy were randomly divided to receive two daily oral Rg3 doses at 20 mg in combination with TACE (n = 152) or TACE alone (n = 76). The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), time to untreatable progression (TTUP), disease control rate (DCR), and safety.

Results

Median overall survival was 13.2 months (95%CI 11.15-15.26) in the TACE + Rg3 group and 10.1 months (95% CI 9.14-11.06) for patients receiving TACE alone (HR 0.63 [95%CI 0.46-0.85], p = 0.002). Median TTP values were 4.3 (95%CI 3.32-5.28) and 3.2 (95%CI 2.51-3.89) months for TACE + Rg3 and TACE patients, respectively, (HR 0.82 [95%CI 0.62-1.08], p = 0.151). TACE + Rg3 treated patients had greater median TTUP (8.3 months [95% CI 7.05-9.55]) compared with 7.3 months [95%CI 6.40-8.20] obtained for the TACE group, (HR 0.76 [95%CI 0.57-1.02], p = 0.063). The most frequently reported Rg3-related grade 3/4 adverse events (constipation, 1.3%; hypertension, 3.9%) were alleviated by symptomatic treatment. Importantly, Rg3 alleviated some TACE-related adverse syndromes (ascites [23.7 vs 48.7%], anorexia [12.5 vs 44.7%], and fatigue [9.9 vs 50.0%], all p < 0.01) and blood anomalies (anemia [36.8 vs 51.3%], leukopenia [46.7 vs 76.3%], thrombocytopenia [32.9 vs 50.0%], and hyperbilirubinemia [17.8 vs 34.2%], all p < 0.05).

Conclusions

In patients with advanced HCC and sufficient liver function, ginsenoside Rg3 improves TACE treatment.

Clinical trial identification

Chinese Clinical Trial Registry (www.chictr.org): ChiCTR-TRC-11001643

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings